symptoms. Therefore, early diagnosis and identification of asymptomatic subjects is of the utmost importance in order to establish rapid treatment and prevent the neurological consequences of this disorder. Most laboratories typically rely on a semi-quantitave analysis for screening of this disorder in the newborn period by testing colorimetric changes of biotinidase enzyme activity in dried blood samples (DBS). However, this approach opens the possibility of impaired quality of enzyme activity in the sample, with the caveat that the mutant DNA remains relatively intact [6] . Consequently, there is a growing interest on developing more precise or adjunctive methodologies for more accurate and rapid diagnosis of this and other potentially treatable disorders. Therefore, the Lindau-Shepard et al. study is a welcome addition to our understanding of diagnostic methods in the newborn period using molecular genotyping and illustrates the advantages of developing supplemental screening tools. Historically, it has been well established the use of real time Polymerase Chain Reaction (PCR) to detect common mutations in the biotinidase gene for early screening of every newborn in the United States [7] . In fact, a comprehensive list of 140 mutations causing biotinidase deficiency was recently reported [8] . While current practices to screen for this disorder consist of using colorimetric analysis of biotinidase enzyme activity in dried blood samples (DBS) obtained during mandated newborn screening prior to discharge from the hospital, Lindau-Shepard et al. developed a microsphere-based array, using a novel method that takes advantage of the multiplex capabilities of the Luminex platform (Luminex Corp, Austin, TX). Furthermore, the authors confirmed all of the detected genotypes in the 22 cases by DNA sequencing. Even though the assay has not been used before for the evaluation of patients with congenital errors of the metabolism such as biotinidase deficiency, certainly, it has been extensively used for microbial detection, gene expression profiling, identification of single nucleotide polymorphisms (SNP) [9] , Human Leukocyte antigen (HLA) DNA typing [10] , and genetic disease screening such as cystic fibrosis [11] . Furthermore, there are several examples of applications in the evaluation of human disease such as Severe Combined Immunodeficiency (SCID) [12, 13] .
In this issue of the Journal of Pediatric Neurology, the authors tested a newly developed multiplexed microsphere-based array genotyping method for the detection of six mutations of the biotinidase gene taking advantage of the multiplexing capabilities of the Luminex platform. The DNA was extracted from dried blood spots (DBS) of biotinidase deficient newborns and the gene sequences containing the mutations of interest were amplified by PCR followed by allele specific primer expansion. Subsequently, the genotypes were verified by sequencing and the results were compared an found concordant for all 6 mutations tested in the twenty-two known biotinidase deficient samples previously identified by the authors using DBS biotinidase enzyme screening. The process was replicated several times to confirm accuracy and the results consistently showed identical genotypes for all tested samples. This feasibility study revealed several advantages: 1) lower amount of genomic DNA needed as compared with non-multiplexed genomic methods, 2) reduced amount of processing time 3) small amount of reagent required due to the application of PCR amplification techniques on the genomic DNA, 4) easily tailored process depending on the laboratory needs by adding or removing microsphere sets, 6) customizable panels of analysis according to geographical mutation prevalence.
A rapid diagnostic tool with the ability to safely and efficiently establish the diagnosis of any neuro-metabolic disorder such as biotinidase deficiency in the first days of life would be an important addition to the diagnostic armamentarium available to screen newborns with a potentially treatable disorder.
Because of the many different mutations associated with biotinidase deficiency, it is clear that DBS screening for biotinidase enzyme activity will remain the primary method for identifying presumptive positives and that follow up blood enzyme analysis will remain the gold standard for confirmation of both partial and profound biotinidase deficiency. However, the addition of a molecular genotyping component to the newborn screening event, as presented in this report, could provide important assistance in the initial evaluation of presumptive positives. For example, the demonstration of a p.D444H mutation without presence of the p.A171T mutation provides very high probability that the newborn will have partial and not profound enzymatic activity [14] . This is because the p.D444H mutation alone without its p.A171T mutation in cis orientation allows for only moderate reduction in enzyme activity. Alternatively, the demonstration of two severe mutations create high probability that the infant has profound biotinidase deficiency.
This type of information can help physicians responsible for following up on presumptive positive results and for subsequently orchestrating referrals of such infants to neurologists or other individuals for further evaluation and treatment.
